Pharmaceutical Contract Manufacturing Market By Services (Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids), End User (Big Pharma, Small Pharma, Generic Pharma, CRO) & Region - Global Forecast to 2026
Updated on : March 30, 2023
The global pharmaceutical contract manufacturing market in terms of revenue was estimated to be worth $120.6 billion in 2021 and is poised to grow at a CAGR of 7.3% from 2021 to 2026.
The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in advanced manufacturing technologies by CDMOs. The increasing demand for biological therapies, the growing focus on specialty medicines, growth in the nuclear medicine sector, and advancements in cell and gene therapies are also expected to offer market growth opportunities in the coming years.
To know about the assumptions considered for the study, Request for Free Sample Report
Pharmaceutical Contract Manufacturing Market Dynamics
Drivers: Patent expiry and increasing demand for generic drugs
Generics are cost-effective drugs with therapeutic effectiveness and safety profiles that are similar to their branded counterparts. One of the major factors driving the growth of the generics market is the increasing pressure to reduce rising healthcare costs. Considering such cost benefits, governments across various countries are promoting the use of generic drugs.
Another major factor driving the growth of the generics market is the expiration of several drugs' patents. In developing countries such as South Korea, around 62 patents covering 158 pharmaceutical products are scheduled to expire in 2021. Although generic erosion because of the patent cliff has resulted in significant revenue and volume losses for the branded drug industry, patent expiration enables the entry of several cheaper generic counterparts in the market (which will boost the volume of drugs sold). This is a positive indicator of market growth, as generics companies outsource around 80% of their production to CDMOs.
Opportunities: Growing demand for cell and gene therapies
Given the personalised nature of cell and gene therapies, they are highly specific and hold the potential to address unmet medical needs associated with treating several disorders. Their promising therapeutic potential has led many pharmaceutical companies and investors to put a significant amount of capital towards developing and commercialising these therapies. As of February 2020, nine cell and gene therapies have been approved by the US FDA. In 2020, around 362 cell and gene therapies were under clinical development. The growing number of cell therapy candidates, coupled with their rapid progression through the various phases of clinical development and their complex manufacturing process, increases the demand for facilities that offer manufacturing services for these therapies.
In 2020, the pharmaceutical contract manufacturing market was dominated by large pharmaceutical companies.
Based on end users, the market is segmented into big pharmaceutical companies, small and medium-sized pharmaceutical companies, generic pharmaceutical companies, and other end users. In 2020, big pharmaceutical companies accounted for the largest share of the pharmaceutical contract development and manufacturing market, and this trend is expected to continue during the forecast period. The large share of this end-user segment can be attributed to factors such as the high demand for end-to-end services in big pharmaceutical companies, rising pricing pressure and pipeline challenges in their operations (resulting in a shift toward contract development and manufacturing), and the growing need to streamline execution costs as a result of the patent expiry of blockbuster drugs.
The biologics manufacturing services segment will witness the highest growth in the pharmaceutical contract manufacturing market during the forecast period.
Based on service, the market is segmented into pharmaceutical manufacturing, biologics manufacturing, and drug development services. In 2020, the biologics manufacturing services segment accounted for the highest growth rate. The major factor driving the growth of this segment is the growing demand for vaccines and biosimilars.
To know about the assumptions considered for the study, download the pdf brochure
Europe was the largest region for pharmaceutical contract manufacturing market in 2020.
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2019, Europe accounted for the largest share of the market, followed by North America and the Asia Pacific. The large share of this regional segment in the global market can primarily be attributed to the large number of clinical trials in the region, the huge API production base, advanced manufacturing capabilities, the presence of leading pharmaceutical companies, and growth in the generics market.
Key players in the pharmaceutical contract manufacturing market include Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), and Siegfried Holding AG (Switzerland)
Pharmaceutical Contract Manufacturing Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$120.6 billion |
|
Estimated Value by 2026 |
$171.3 billion |
|
Growth Rate |
poised to grow at a CAGR of 7.3% |
|
Market Segmentation |
Service, End User & Region |
|
Market Drivers |
|
|
Market Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
This report categorizes the global pharmaceutical contract manufacturing market into the following segments and sub-segments:
By Services
-
Pharmaceutical Manufacturing Services
- Pharmaceutical API Manufacturing Services
-
Pharmaceutical FDF Manufacturing Services
- Parenteral/injectable manufacturing services
- Tablet manufacturing services
- Capsule manufacturing services
- Oral liquid manufacturing services
- Semi-solid manufacturing services
- Other formulations manufacturing services
- Drug Development Services
-
Biologics Manufacturing Services
- Biologics API manufacturing services
- Biologics FDF manufacturing services
By End User
- Big Pharmaceutical Companies
- Small & Medium-Sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Other End Users
By Region
-
Europe
- Germany
- Italy
- France
- UK
- Switzerland
- Spain
- Poland
- Rest of Europe (RoE)
-
North America
- US
- Canada
-
Asia Pacific (APAC)
- China
- India
- South Korea
- Japan
- Rest of Asia Pacific (RoAPAC)
- Latin America
- Middle East and Africa
Recent Developments
- In 2021, Samsung BioLogics (South Korea) entered into a Development and Manufacturing Agreement with Kineta (US) for Anti-VISTA Antibody Immunotherapy
- In 2021, Lonza Group (Switzerland) entered into an agreement with Aruvant Science (US) to carry out process development (one-time investigational gene therapy—ARU-1801) for sickle-cell treatment in the US
- In 2020, Catalent (US) acquired Skeletal Theray Support (Belgium). Under this acquisition, Catalent manufactured clinical material for Bone Therapeutics’ drug, ALLOB, an allogeneic osteoblastic cell therapy product
- In 2020, Recipharm AB (Sweden) acquired Consort Medical (UK) Bespak division dealing with inhalation and other devices
Frequently Asked Questions (FAQs):
What is the projected market value of the global pharmaceutical contract manufacturing market?
The global market of pharmaceutical contract manufacturing is projected to reach USD 171.3 billion.
What is the estimated growth rate (CAGR) of the global pharmaceutical contract manufacturing market for the next five years?
The global pharmaceutical contract manufacturing market is projected to grow at a Compound Annual Growth Rate (CAGR) of 7.3% from 2021 to 2026.
What are the major revenue pockets in the pharmaceutical contract manufacturing market currently?
The market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2019, Europe accounted for the largest share of the pharmaceutical contract manufacturing market, followed by North America and the Asia Pacific. The large share of this regional segment in the global market can primarily be attributed to the large number of clinical trials in the region, the huge API production base, advanced manufacturing capabilities, the presence of leading pharmaceutical companies, and growth in the generics market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 37)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 41)
2.1 RESEARCH APPROACH
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 1 BREAKDOWN OF PRIMARIES: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
2.2 MARKET DATA ESTIMATION & TRIANGULATION
FIGURE 2 DATA TRIANGULATION METHODOLOGY
2.3 MARKET ESTIMATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION APPROACH: COMPANY REVENUE ANALYSIS-BASED ESTIMATION
FIGURE 4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE (USD BILLION): FINAL MARKET SIZE
2.4 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 5 FINAL CAGR PROJECTIONS (2021−2026)
2.5 INSIGHTS FROM PRIMARIES
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
3 EXECUTIVE SUMMARY (Page No. - 47)
FIGURE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY SERVICE, 2020
FIGURE 8 BIOLOGICS MANUFACTURING SERVICES MARKET SHARE, BY TYPE, 2020
FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021 VS. 2026 (USD BILLION)
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
4 PREMIUM INSIGHTS (Page No. - 50)
4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
FIGURE 11 GROWING DEMAND FOR GENERICS IS ONE OF THE KEY FACTORS DRIVING MARKET GROWTH
4.2 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
FIGURE 12 PHARMACEUTICAL MANUFACTURING SERVICES TO COMMAND THE LARGEST SHARE OF THE EUROPEAN MARKET
4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER
FIGURE 13 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES TO GROW AT THE HIGHEST RATE DURING THE FORECAST PERIOD
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES BETWEEN 2021 & 2026
5 MARKET OVERVIEW (Page No. - 54)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
5.2.1 DRIVERS
5.2.1.1 Patent expiry and increasing demand for generic drugs
5.2.1.2 Increasing investments in pharmaceutical R&D
FIGURE 16 NUMBER OF PHARMA COMPANIES WITH ACTIVE DRUG PIPELINE PROJECTS (2010–2020)
FIGURE 17 GLOBAL R&D SPENDING (2016–2020)
5.2.1.3 Investments in advanced manufacturing technologies by CDMOs
5.2.2 OPPORTUNITIES
5.2.2.1 Increasing demand for biological therapies
5.2.2.2 Growth in the nuclear medicine sector
5.2.2.3 Growing demand for cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Introduction of serialization
5.2.4 TRENDS
5.2.4.1 Expansion in emerging countries
5.2.4.2 CDMO industry consolidation
TABLE 1 LIST OF ACQUISITIONS
5.3 VALUE CHAIN ANALYSIS
FIGURE 18 VALUE CHAIN ANALYSIS OF THE MARKET
5.4 ECOSYSTEM MARKET MAP
FIGURE 19 ECOSYSTEM OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
5.5 SUPPLY CHAIN
5.6 IMPACT OF THE COVID-19 PANDEMIC ON THE GROWTH OF THE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
TABLE 2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
5.6.1 IMPACT ON THE MARKET
FIGURE 20 PRE-COVID VS. POST-COVID-19 SCENARIO, 2019–2021
5.7 REGULATORY ASSESSMENT
5.7.1 INTRODUCTION
5.8 PORTERS FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 THREAT OF SUBSTITUTES
5.8.3 BARGAINING POWER OF SUPPLIERS
5.8.4 BARGAINING POWER OF BUYERS
5.8.5 DEGREE OF COMPETITION
6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE (Page No. - 68)
6.1 INTRODUCTION
TABLE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
6.2 PHARMACEUTICAL MANUFACTURING SERVICES
TABLE 5 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 6 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 7 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 8 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
6.2.1.1 Need to cut costs and ensure focus on core areas leads companies to outsource API manufacturing
TABLE 9 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 10 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
TABLE 11 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 12 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
6.2.2.1 Parenteral/injectable manufacturing services
6.2.2.1.1 Need for high levels of expertise and growing drug development activities are driving the demand for contract manufacturing
TABLE 13 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 14 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.2.2.2 Tablet manufacturing services
6.2.2.2.1 Shifting manufacturing requirements and the need to streamline production processes are driving market growth
TABLE 15 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 16 TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.2.2.3 Capsule manufacturing services
6.2.2.3.1 Growth in demand for capsule formulations has ensured growth opportunities for service providers
TABLE 17 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 18 CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.2.2.4 Oral liquid manufacturing services
6.2.2.4.1 Complexities involved in oral liquid manufacturing have prompted companies to opt for outsourcing
TABLE 19 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 20 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.2.2.5 Semi-solid manufacturing services
6.2.2.5.1 Demand for specific manufacturing facilities and packaging to boost the outsourcing of semi-solids
TABLE 21 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 22 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.2.2.6 Other formulations manufacturing services
TABLE 23 OTHER FORMULATIONS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 24 OTHER FORMULATIONS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.3 DRUG DEVELOPMENT SERVICES
6.3.1 DRUG SUBSTANCE COMPLEXITY AND HIGH COSTS HAVE SUPPORTED THE OUTSOURCING OF DRUG DEVELOPMENT
TABLE 25 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 26 DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.4 BIOLOGICS MANUFACTURING SERVICES
TABLE 27 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 28 BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
6.4.1 BIOLOGICS API MANUFACTURING SERVICES
6.4.1.1 Market for biologics API manufacturing is still in the nascent phase
TABLE 29 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 30 BIOLOGICS API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
6.4.2.1 Increasing R&D costs and process complexity have prompted the shift toward contract manufacturing
TABLE 31 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 32 BIOLOGICS FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER (Page No. - 95)
7.1 INTRODUCTION
TABLE 33 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 34 MARKET, BY END USER, 2021–2026 (USD MILLION)
7.2 BIG PHARMACEUTICAL COMPANIES
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO THE GROWTH OF THIS MARKET
TABLE 35 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 36 PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2026 (USD MILLION)
7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
7.3.1 DEMAND IN BIOLOGICS DRUG DEVELOPMENT AND HIGH PRICING PRESSURE TO BOOST THE MARKET GROWTH
TABLE 37 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 38 MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2026 (USD MILLION)
7.4 GENERIC PHARMACEUTICAL COMPANIES
7.4.1 GROWING DEMAND FOR GENERICS TO SUPPORT MARKET GROWTH
TABLE 39 PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 40 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2026 (USD MILLION)
7.5 OTHER END USERS
TABLE 41 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 42 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2026 (USD MILLION)
8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION (Page No. - 106)
8.1 INTRODUCTION
FIGURE 21 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT
TABLE 43 MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 44 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2021–2026 (USD MILLION)
8.2 EUROPE
FIGURE 22 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT
TABLE 45 EUROPE: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 46 EUROPE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 47 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 48 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 49 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 50 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 51 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 52 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 53 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 54 EUROPE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 55 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 56 EUROPE: MARKET, BY END USER, 2021–2026 (USD MILLION)
8.2.1 GERMANY
8.2.1.1 High healthcare expenditure and increased pharmaceutical production to support market growth
TABLE 57 GERMANY: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 58 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 59 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 60 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 61 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 62 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 63 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 64 GERMANY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 65 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 66 GERMANY: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.2.2 ITALY
8.2.2.1 Increasing focus on clinical research and the growing popularity of branded drugs are driving the demand for contract development and manufacturing
TABLE 67 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 68 ITALY: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 69 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 70 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 71 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 72 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 73 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 74 ITALY: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 75 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 76 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.2.3 FRANCE
8.2.3.1 Presence of leading pharmaceutical companies to support market growth in France
TABLE 77 FRANCE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 78 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 79 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 80 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 81 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 82 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 83 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 84 FRANCE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 85 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 86 FRANCE: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY END USER, 2021–2026 (USD MILLION)
8.2.4 UK
8.2.4.1 Growth in the generics market and the rising cost of manufacturing parenteral formulations are driving market growth
TABLE 87 UK: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 88 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 89 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 90 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 91 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 92 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 93 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 94 UK: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 95 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 96 UK: MARKET, BY END USER, 2021–2026 (USD MILLION)
8.2.5 SWITZERLAND
8.2.5.1 Large volume of pharmaceutical production and growing scope for generics to provide growth opportunities
TABLE 97 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 98 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 99 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 100 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 101 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 102 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 103 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 104 SWITZERLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 105 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 106 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.2.6 SPAIN
8.2.6.1 Increase in biologics production to support market growth
TABLE 107 SPAIN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 108 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 109 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 110 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 111 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 112 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 113 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 114 SPAIN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 115 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 116 SPAIN: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY END USER, 2021–2026 (USD MILLION)
8.2.7 POLAND
8.2.7.1 Rising public expenditure on healthcare to support the market growth in Poland
TABLE 117 POLAND: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 118 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 119 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 120 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 121 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 122 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 123 POLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 124 POLAND: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 125 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 126 POLAND: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY END USER, 2021–2026 (USD MILLION)
8.2.8 REST OF EUROPE
TABLE 127 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 128 ROE: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 129 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 130 ROE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 131 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 132 ROE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 133 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 134 ROE: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 135 ROE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 136 ROE: MARKET, BY END USER, 2021–2026 (USD MILLION)
8.3 NORTH AMERICA
TABLE 137 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 138 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 139 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 140 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 141 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 142 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 143 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 144 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 145 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 146 NORTH AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 147 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 148 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.3.1 US
8.3.1.1 The US dominates the North American pharmaceutical contract manufacturing market
TABLE 149 US: PHARMACEUTICAL CONTRACT DEVELOPMENT MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 150 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 151 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 152 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 153 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 154 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 155 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 156 US: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 157 US: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 158 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.3.2 CANADA
8.3.2.1 Growth of the emerging markets and slowdown in new product approvals will hamper the market growth
TABLE 159 CANADA: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 160 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 161 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 162 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 163 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 164 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 165 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 166 CANADA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 167 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 168 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.4 ASIA PACIFIC
FIGURE 23 ASIA PACIFIC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET SNAPSHOT
TABLE 169 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 170 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2026 (USD MILLION)
TABLE 171 ASIA PACIFIC: MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 172 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 173 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 174 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 175 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 176 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 177 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 178 ASIA PACIFIC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 179 ASIA PACIFIC: MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 180 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.4.1 CHINA
8.4.1.1 Favorable government regulations are fueling market growth in China
TABLE 181 CHINA: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 182 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 183 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 184 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 185 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 186 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 187 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 188 CHINA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 189 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 190 CHINA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.4.2 INDIA
8.4.2.1 Low manufacturing costs and a skilled workforce are factors attracting outsourcing and investment to India
TABLE 191 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 192 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 193 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 194 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 195 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 196 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 197 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 198 INDIA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 199 INDIA: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 200 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.4.3 SOUTH KOREA
8.4.3.1 Government investments are a key contributor to market growth in South Korea
TABLE 201 SOUTH KOREA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 202 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 203 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 204 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 205 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 206 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 207 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 208 SOUTH KOREA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
8.4.4 JAPAN
8.4.4.1 Growing generics demand and government initiatives to drive the demand for contract manufacturing of drugs
TABLE 209 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 210 JAPAN: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 211 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 212 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 213 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 214 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 215 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 216 JAPAN: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 217 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 218 JAPAN: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.4.5 REST OF ASIA PACIFIC
TABLE 219 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 220 ROAPAC: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 221 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 222 ROAPAC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 223 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 224 ROAPAC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 225 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 226 ROAPAC: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 227 ROAPAC: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 228 ROAPAC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2026 (USD MILLION)
8.5 LATIN AMERICA
8.5.1 FAVORABLE COST STRUCTURE AND GOVERNMENT INVESTMENTS TO DRIVE PHARMACEUTICAL PRODUCTION IN LATAM
TABLE 229 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 230 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 231 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 232 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 233 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 234 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 235 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 236 LATIN AMERICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 237 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 238 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY END USER, 2021–2026 (USD MILLION)
8.6 MIDDLE EAST & AFRICA
8.6.1 GOVERNMENT SUPPORT TO BOOST LOCAL PRODUCTION IS EXPECTED TO OFFER GROWTH OPPORTUNITIES FOR CONTRACT MANUFACTURERS IN THE REGION
TABLE 239 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE, 2017–2020 (USD MILLION)
TABLE 240 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2026 (USD MILLION)
TABLE 241 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 242 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 243 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 244 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 245 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 246 MIDDLE EAST & AFRICA: BIOLOGICS MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2026 (USD MILLION)
TABLE 247 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 248 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET, BY END USER, 2021–2026 (USD MILLION)
9 COMPETITIVE LANDSCAPE (Page No. - 189)
9.1 OVERVIEW
9.2 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
9.3 MARKET SHARE ANALYSIS
FIGURE 25 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET RANK, BY KEY PLAYER, 2020
TABLE 249 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION
9.4 COMPETITIVE LEADERSHIP MAPPING
9.4.1 STARS
9.4.2 EMERGING LEADERS
9.4.3 PERVASIVE PLAYERS
9.4.4 PARTICIPANTS
FIGURE 26 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT (2020)
9.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: START-UP/SME EVALUATION MATRIX, 2020
9.5.1 PROGRESSIVE COMPANIES
9.5.2 STARTING BLOCKS
9.5.3 RESPONSIVE COMPANIES
9.5.4 DYNAMIC COMPANIES
FIGURE 27 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: START-UP/SME EVALUATION MATRIX, 2020
9.6 COMPANY SERVICE FOOTPRINT
TABLE 250 SERVICE PORTFOLIO ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET
9.7 COMPANY GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN THE PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET
TABLE 251 GEOGRAPHIC REVENUE MIX: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET (2020)
9.8 COMPETITIVE SCENARIO
TABLE 252 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: SERVICE LAUNCHES, MAY 2019–OCTOBER 2020
TABLE 253 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, MARCH 2019–AUGUST 2021
TABLE 254 PHARMACEUTICAL CONTRACT DEVELPOMENT MARKET: OTHERS, MAY 2019–AUGUST 2021
10 COMPANY PROFILES (Page No. - 202)
(Business Overview, Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1 MAJOR PLAYERS
10.1.1 LONZA GROUP
TABLE 255 LONZA GROUP: BUSINESS OVERVIEW
FIGURE 28 LONZA GROUP: COMPANY SNAPSHOT (2020)
TABLE 256 LONZA GROUP: SERVICES OFFERED
10.1.2 THERMO FISHER SCIENTIFIC INC.
TABLE 257 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
FIGURE 29 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
TABLE 258 THERMO FISHER SCIENTIFIC: SERVICES OFFERED
10.1.3 CATALENT
TABLE 259 CATALENT: BUSINESS OVERVIEW
FIGURE 30 CATALENT: COMPANY SNAPSHOT (2020)
TABLE 260 CATALENT: SERVICES OFFERED
10.1.4 RECIPHARM AB
TABLE 261 RECIPHARM AB: BUSINESS OVERVIEW
FIGURE 31 RECIPHARM AB: COMPANY SNAPSHOT
TABLE 262 RECIPHARM AB: SERVICES OFFERED
10.1.5 ABBVIE
TABLE 263 ABBVIE: BUSINESS OVERVIEW
FIGURE 32 ABBVIE: COMPANY SNAPSHOT (2020)
TABLE 264 ABBVIE: SERVICES OFFERED
10.1.6 SIEGFRIED HOLDING AG
TABLE 265 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW
FIGURE 33 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2020)
TABLE 266 SIEGFRIED HOLDING AG: SERVICES OFFERED
10.1.7 EVONIK INDUSTRIES
TABLE 267 EVONIK INDUSTRIES: BUSINESS OVERVIEW
FIGURE 34 EVONIK INDUSTRIES: COMPANY SNAPSHOT (2020)
TABLE 268 EVONIK INDUSTRIES: SERVICES OFFERED
10.1.8 BOEHRINGER INGELHEIM
TABLE 269 BOEHRINGER INGELHEIM: BUSINESS OVERVIEW
FIGURE 35 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2020)
TABLE 270 BOEHRINGER INGELHEIM: SERVICES OFFERED
10.1.9 PIRAMAL PHARMA SOLUTIONS
TABLE 271 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW
FIGURE 36 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2020)
TABLE 272 PIRAMAL PHARMA SOLUTIONS: SERVICES OFFERED
10.1.10 SAMSUNG BIOLOGICS
TABLE 273 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
FIGURE 37 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2020)
TABLE 274 SAMSUNG BIOLOGICS: SERVICES OFFERED
10.1.11 WUXI APPTEC (WUXI STA)
TABLE 275 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 38 WUXI APPTEC: COMPANY SNAPSHOT (2020)
TABLE 276 WUXI APPTEC: SERVICES OFFERED
10.1.12 FUJIFILM HEALTHCARE
TABLE 277 FUJIFILM HEALTHCARE: BUSINESS OVERVIEW
FIGURE 39 FUJIFILM HEALTHCARE: COMPANY SNAPSHOT (2020)
TABLE 278 FUJIFILM HEALTHCARE: SERVICES OFFERED
10.2 OTHER PLAYERS
10.2.1 VETTER PHARMA INTERNATIONAL
TABLE 279 VETTER PHARMA INTERNATIONAL: BUSINESS OVERVIEW
TABLE 280 VETTER PHARMA INTERNATIONAL: SERVICES OFFERED
10.2.2 FAMAR HEALTH CARE SERVICES
TABLE 281 FAMAR HEALTH CARE SERVICES: BUSINESS OVERVIEW
TABLE 282 FAMAR HEALTH CARE SERVICES: SERVICES OFFERED
10.2.3 AENOVA GROUP
TABLE 283 AENOVA GROUP: BUSINESS OVERVIEW
TABLE 284 AENOVA GROUP: SERVICES OFFERED
10.2.4 ALMAC GROUP
10.2.5 CAMBREX
10.2.6 CORDENPHARMA
10.2.7 BIOVECTRA
10.2.8 CURIA (FORMERLY ALBANY MOLECULAR RESEARCH)
*Details on Business Overview, Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
11 APPENDIX (Page No. - 246)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 AVAILABLE CUSTOMIZATIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the pharmaceutical contract manufacturing market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the pharmaceutical contract development and manufacturing market. The secondary sources used for this study include Some of the key secondary sources referred to for this study include publications from government sources (such as the Indian Pharmaceutical Association (IPA), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Central Drugs Standard Control Organisation (CDSCO), Indian Brand Equity Foundation (IBEF), Pharma & Biopharma Outsourcing Association (PBOA), Generics and Biosimilars Initiative (GaBI), PharmaTimes, Parenteral Drug Association (PDA), Indian Drug Manufacturers’ Association (IDMA), World Journal of Pharmaceutical Sciences. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the pharmaceutical contract development and manufacturing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the pharmaceutical contract development and manufacturing business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the pharmaceutical contract development and manufacturing market based on service, end user and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities and trends)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall pharmaceutical contract development and manufacturing market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the pharmaceutical contract development and manufacturing market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- An additional five company profiles
Growth opportunities and latent adjacency in Pharmaceutical Contract Manufacturing Market
What will be the key challenges for business in the pharmaceutical contract manufacturing market in the near future?
Key players in pharmaceutical contract manufacturing industry for North America region include:
Who are the top key players in the pharmaceutical contract manufacturing market in North America?